Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lush

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Clinical Breast Cancer|December 14, 2021
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)Julie A Means-Powell, Ingrid A Mayer, Roohi Ismail-Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I study of a novel taxane BMS-188797 in adult patients with solid malignanciesChristopher R Garrett, Mayer N Fishman, Randall R Rago, et al.
Journal of Clinical Pharmacology|April 10, 1999
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosisH K Cho, R M Lush, D L Bartlett, et al.
Annals of Internal Medicine|June 1, 1997
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxinA M Senderowicz, E Vitetta, D Headlee, et al.
The Annals of Pharmacotherapy|October 2, 2003
Clinical pharmacology of flavopiridol following a 72-hour continuous infusionMichelle A Rudek, Kenneth S Bauer, Richard M Lush, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2012
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancerRichard M Lush, Amita Patnaik, Daniel Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2011
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlatesJanelle B Perkins, Steven C Goldstein, Jana L Dawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignanciesMayer N Fishman, Christopher R Garrett, George R Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasmsE A Sausville, S G Arbuck, R Messmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinomaBert H O'Neil, Laura W Goff, John Sae Wook Kauh, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Clinical Breast Cancer|December 14, 2021
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)Julie A Means-Powell, Ingrid A Mayer, Roohi Ismail-Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I study of a novel taxane BMS-188797 in adult patients with solid malignanciesChristopher R Garrett, Mayer N Fishman, Randall R Rago, et al.
Journal of Clinical Pharmacology|April 10, 1999
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosisH K Cho, R M Lush, D L Bartlett, et al.
Annals of Internal Medicine|June 1, 1997
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxinA M Senderowicz, E Vitetta, D Headlee, et al.
The Annals of Pharmacotherapy|October 2, 2003
Clinical pharmacology of flavopiridol following a 72-hour continuous infusionMichelle A Rudek, Kenneth S Bauer, Richard M Lush, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2012
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancerRichard M Lush, Amita Patnaik, Daniel Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2011
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlatesJanelle B Perkins, Steven C Goldstein, Jana L Dawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignanciesMayer N Fishman, Christopher R Garrett, George R Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasmsE A Sausville, S G Arbuck, R Messmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinomaBert H O'Neil, Laura W Goff, John Sae Wook Kauh, et al.
Pageof 7